GACP Certification Awarded to Internationally-Based Extracts Company
A multinational, pharmaceutical-grade medical cannabis and hemp extracts company, Clever Leaves, was recently granted a good agricultural and collecting practices (GACP) certification by the Control Union Medical Cannabis Standard (CUMCS) for meeting their guidelines for consistency and quality in the cultivation and harvest of medicinal cannabis.
A multinational, pharmaceutical-grade medical cannabis and hemp extracts company, Clever Leaves, was recently granted a good agricultural and collecting practices (GACP) certification by the Control Union Medical Cannabis Standard (CUMCS) for meeting their guidelines for consistency and quality in the cultivation and harvest of medicinal cannabis (1).
CUMCS’s standards offer general technical guidance for obtaining high-quality medicinal plant materials for the sustainable production of herbal items categorized as medicinal products. With the GACP certification, Clever Leaves is able to show that they operate under CUMCS procedures, cultivating crops that are free of heavy metals and agrochemicals as well as protocols for biodiversity safety in pharmaceutical manufacturing.
In Clever Leaves press release the company stated (1): “The CUMCS certification standard is based on GACP guidelines of The World Health Organization (WHO), the GACP Guidelines of the European Medicines Agency, Guidelines of the Dutch Government for Cannabis for Medical Use, and the International Standard for Good Agriculture Practice.”
“GACP certification reflects Clever Leaves’ ability to produce pharmaceutical-grade cannabis as well as our adherence to stringent operational standards,” said Kyle Detwiler, the CEO of Clever Leaves (1). “Achieving internationally-recognized quality guidelines will enable us to bring value at every touch point of the supply chain.”
With the GACP certification, Clever Leaves will be able to export pharmaceutical-grade cannabis products to international markets.
References:
Ep 24, Part I: Data Transparency in Cannabis Testing with Yasha Khan
November 21st 2024Evan Friedmann interviews Yasha Khan, co-founder of MCR Labs, about his journey into the cannabis industry and his efforts to promote transparency and integrity in laboratory practices. Yasha discusses the origins of MCR Labs, which began in Massachusetts to meet the needs of the soon-to-be legal medical cannabis market. He explains the challenges faced, including result manipulation by labs and the impact on public health. Yasha's Freedom of Information Act (FOIA) project aimed to gather testing data from 37 states, revealed significant discrepancies in potency and mold results. Despite some states' reluctance to share data, Yasha has made much of this data public, leading to collaborative research and publications on various aspects of cannabis testing.
Assessing Cannabis as a Harm Reduction Strategy: Insights from a Large-Scale Study
November 19th 2024A New Zealand study aimed to assess cannabis use as a harm reduction tool. Findings highlight lifestyle factors, and suggest cannabis-focused harm reduction strategies in reducing other substance use such as alcohol.
Ep 23, Part III: Accreditation in the Cannabis Industry with Susan Audino
October 24th 2024In Part III of this episode, host Evan Friedmann is joined by Susan Audino, PhD, founder of S.A. Audino & Associates, LLC, and co-founder of Saturn Scientific, LLC, to examine the complexities of sampling in the cannabis industry, emphasizing the need for proper sampling plans, and methods.
